Beta2-agonists act primarily to relax airway smooth muscle by stimulating beta2-receptors, which in turn increase cyclic AMP and produce functional antagonism to bronchoconstriction. Long-term control medications for persons with asthma include corticosteroids, cromolyn sodium and nedocromil, methylxanthines, leukotriene modifiers, and long-acting beta2-agonists (LABAs). Medications for quick relief of bronchoconstriction and acute symptoms include short-acting beta2-agonists (SABAs) and anticholinergics. COPD is a slowly progressive disease of the airways that is characterized by a gradual loss of lung function. Since airflow obstruction is present in all persons with COPD, bronchodilators (beta2-agonists, anticholinergic drugs, and methylxanthines) are a key part of therapy. The purpose of this review is to compare the benefits and harms of different beta2-agonists.
Copyright © 2006, Oregon Health & Science University, Portland, Oregon.